EUVIMEDEUVIMED entdecken
Crossref

Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression

Imen Becetti, Hannah Lamont, Luke Dysart, Elisa Asanza, Christiane Tolley, Katherine Holman, Caroline Mitchell, Sharon Dekel, Nouchine Hadjikhani, Hang Lee, Caitlin T Ravichandran, C Sue Carter und 4 weitere

Contemporary Clinical Trials · 2026-09 · 168 · 108399

DOI: 10.1016/j.cct.2026.108399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026-09. Verfasst von Imen Becetti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Division of Pediat…. Hauptthemen laut MEDLINE: Depression, Postpartum, Limosilactobacillus reuteri, Object Attachment, Probiotics. Die Arbeit nennt 80 Literaturangaben. Gefördert von: John Templeton Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Postpartum depression (PPD) is common and can impair early mother-infant bonding. Oxytocin (OXT) supports socioemotional adaptation, yet intranasal OXT yields supraphysiological exposure and mixed results. The probiotic Limosilactobacillus reuteri (L. reuteri) increases endogenous oxytocin levels in rodents, suggesting that it may enhance OXT signaling via gut-brain pathways in humans. We designed a proof-of-concept trial to test whether postpartum L. reuteri improves early mother-infant bonding and maternal mental health, impulse control, and emotion recognition. METHODS In this randomized, double-blind, placebo-controlled trial, mothers aged ≥18 years at elevated PPD risk (history of depression, prior PPD, and/or increased prenatal depressive symptoms) received 6 weeks of once-daily L. reuteri or placebo, stratified by delivery mode (vaginal/Cesarean section). The primary endpoint is mother-infant bonding quality at Week 6; secondary endpoints include maternal mental health, impulse control, and emotion recognition at Week 6. Salivary OXT at Week 2 serves as a mechanistic endpoint. RESULTS Forty-six participants (mean age ± SD: 34.3 ± 4.5 years) were enrolled and randomized; 38 (82.6%) completed the Week-6 visit. Baseline characteristics are reported. CONCLUSION This trial evaluates whether a lactation-compatible L. reuteri intervention targeting endogenous OXT improves early mother-infant bonding and maternal well-being. Findings will inform feasibility, safety, and effect size estimates, clarify OXT's mechanistic role in PPD pathophysiology, and guide development of microbiome-based therapeutics for perinatal mental health. TRIAL REGISTRATION NUMBER ClinicalTrials.gov: NCT04472065.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Depression, PostpartumLimosilactobacillus reuteriObject AttachmentProbioticsMother-Child RelationsHumansFemaleDouble-Blind MethodAdultRandomized Controlled Trials as TopicOxytocinEmotions

Stichwörter der Autor:innen

Emotion recognitionImpulse controlLimosilactobacillus reuteri (L. reuteri)Maternal mental healthMother-infant bondingMother-infant dyadOxytocinPostpartum depressionPostpartum mothers

Substanzen

Oxytocin

Autor:innen und Institutionen

  • Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Division of Pediatric Endocrinology, Department of Pediatrics, Mass General Hospital for…
  • Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
  • Vincent Center for Reproductive Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
  • Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
  • Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United States.
  • Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

Förderung

  • John Templeton Foundation

Zitieren

APA

Becetti, I., Lamont, H., Dysart, L., Asanza, E., Tolley, C., Holman, K., Mitchell, C., Dekel, S., Hadjikhani, N., Lee, H., Ravichandran, C. T., Carter, C. S., Kingsbury, M. A., Erdman, S. E., Plessow, F., & Lawson, E. A. (2026). Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression. Contemporary Clinical Trials, 168, 108399. https://doi.org/10.1016/j.cct.2026.108399

Vancouver

Becetti I, Lamont H, Dysart L, Asanza E, Tolley C, Holman K, et al. Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression. Contemporary Clinical Trials. 2026;168:108399. doi:10.1016/j.cct.2026.108399

BibTeX
@article{Becetti2026,
  author = {Becetti, Imen and Lamont, Hannah and Dysart, Luke and Asanza, Elisa and Tolley, Christiane and Holman, Katherine and Mitchell, Caroline and Dekel, Sharon and Hadjikhani, Nouchine and Lee, Hang and Ravichandran, Caitlin T and Carter, C Sue and Kingsbury, Marcy A and Erdman, Susan E and Plessow, Franziska and Lawson, Elizabeth A},
  title = {Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  volume = {168},
  pages = {108399},
  doi = {10.1016/j.cct.2026.108399}
}
Kostenlos starten →